Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Key takeaways of recent quarter & conference call highlights
The stability is led by healthy demand in the domestic and emerging markets
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
